# US 2023/0053342 A1 · Imidazolidinone compound, preparation method therefor and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0053342 A1
- Document ID: US20230053342A1
- Status: Published application
- Kind: A1
- Application number: 17/773,771
- Filed: 2020-11-04
- Published: 2023-02-23
- Earliest claimed: 2019-11-04
- Assignees: Betta Pharmaceuticals Co., Ltd.
- Applicants: Betta Pharmaceuticals Co., Ltd
- Inventors: Houxian ZU; Xizhen SONG; Kai CHEN; Xiangyong LIU; Jie CHEN; Yajing BIAN; Lieming DING; Jiabing WANG
- Web page: https://patentgrep.com/patent/US20230053342A1

## CPC

- C07D 498/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An imidazolidinone compound represented by formula (I), or a stereoisomer thereof, a geometric isomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, a synthesis method therefor and use thereof.

## Claims

### Claim 1

A compound of Formula (I) or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof,
wherein,
X is selected from O and S;
R1 is selected from H, CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 heterocyclyl, C6-8 aryl, C5-8 heteroaryl, ORa and —NRaRb; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 heterocyclyl, C6-8 aryl and C5-8 heteroaryl are each optionally substituted with one or more substituents selected from halogen, CN, ORa, oxo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl and C3-6 heterocyclyl;
R2 is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 heterocyclyl, C6-8 aryl, C5-8 heteroaryl; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 heterocyclyl, C6-8 aryl and C5-8 heteroaryl are each optionally substituted with one or more substituents selected from halogen, CN, —OH, —NO2, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C2-6 alkynyl, C2-6 haloalkynyl, C3-6 cycloalkyl, C3-6 halocycloalkyl, C3-6 heterocyclyl, C3-6 haloheterocyclyl, C6-8 aryl, C6-8 haloaryl, C5-8 heteroaryl, C5-8 haloheteroaryl, oxo, —ORa, —NRaRb, —C(O)Ra, —C(O)O Ra, —C(O)NRaRb, —S(O)Ra and —S(O)2Ra;
R3 is selected from H, halogen, CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, —ORa and —NRaRb; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl are each optionally substituted with one or more substituents selected from halogen, CN, —ORa, —NRaRb, —C(O)Ra, —C(O)ORa, —C(O)NRaRb, —S(O)Ra and —S(O)2Ra;
R4 is selected from H, halogen, CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, oxo, C1-6 haloalkyl, C2-6 haloalkenyl, C2-6 haloalkynyl, C1-6 alkoxy, C1-6 halo alkoxy, —ORa, —NRaRb, —C(O)Ra, —C(O)ORa, —C(O)NRaRb, —S(O)Ra and —S(O)2Ra;
R5 is selected from H, halogen, CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C2-6 haloalkenyl, C2-6 haloalkynyl, C1-6 alkoxy, C1-6 haloalkoxy, —ORa, —NRaRb, —S(O)Ra and —S(O)2Ra;
R6 is selected from H, halogen, CN, oxo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-6 cycloalkyl, C3-6 heterocyclyl, C6-8 aryl, C5-8 heteroaryl, —ORa, —NRaRb, —C(O)Ra, —C(O)O Ra, —C(O) NRaRb, —S(O)Ra and —S(O)2Ra; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-6 cycloalkyl, C3-6 heterocyclyl, C6-8 aryl and C5-8 heteroaryl are each optionally substituted with one or more substituents selected from halogen, CN, oxo, —NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, —ORa, —NRaRb, —C(O)Ra, —C(O)O Ra, —C(O)NRaRb, —S(O)Ra and —S(O)2Ra; or,
two R6 take with the C atoms which they are attached to form C3-6 cycloalkyl or C3-6 heterocyclyl;
Ra and Rb are independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-6 cycloalkyl, C3-6 heterocyclyl, C6-8 aryl, C5-8 heteroaryl; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-6 cycloalkyl, C3-6 heterocyclyl, C6-8 aryl, C5-8 heteroaryl are optionally substituted with halogen, CN, —OH, —NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy;
m is selected from 0, 1, 2, 3 and 4;
n is selected from 0, 1, 2 and 3; and
y is selected from 0, 1, 2, 3, 4, 5 and 6.

### Claim 2 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein R1 is C1-6 alkyl or C3-6 cycloalkyl, said C1-6 alkyl and C3-6 cycloalkyl can be substituted optionally and independently with halogen.

### Claim 3 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein R2 is selected from H, C1-6 alkyl, C3-6 cycloalkyl, C3-6 heterocyclyl, C6-8 aryl and C5-8 heteroaryl; said C1-6 alkyl, C3-6 cycloalkyl, C3-6 heterocyclyl, C6-8 aryl and C5-8 heteroaryl are each optionally substituted with one or more substituents selected from halogen, —CN, —OH, —NRaRb, C1-6 alkyl and C1-6 haloalkyl; said Ra and Rb are independently selected from H and C1-6 alkyl.

### Claim 4 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein R3 is selected from H, halogen, CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C2-6 haloalkenyl and C2-6 haloalkynyl.

### Claim 5 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein R6 is selected from H, halogen, CN, —NH2, oxo, —OH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C2-6 haloalkenyl, C2-6 haloalkynyl, C3-6 cycloalkyl, C3-6 heterocyclyl, C6-8 aryl and C5-8 heteroaryl.

### Claim 6 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein the compound is of Formula (II):

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein R3 is selected from H, halogen, C1-6 alkyl and C2-6 alkenyl.

### Claim 10 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein R4 and R5 are both H.

### Claim 11 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein the compound is of Formula (III):
wherein:
R1 is C1-6 alkyl or C1-6 haloalkyl;
R2 is selected from H, C1-6 alkyl, C3-6 cycloalkyl, C3-6 heterocyclyl, C6-8 aryl and C5-8 heteroaryl; wherein C1-6 alkyl, C3-6 cycloalkyl, C3-6 heterocyclyl, C6-8 aryl and C5-8 heteroaryl are each optionally substituted with one or more substituents selected from halogen, —CN, —OH, —NRaRb, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy and C1-6 halo alkoxy;
R3 is selected from H, halogen, C1-6 alkyl and C2-6 alkenyl;
R6 is selected from H, halogen, —NH2, oxo, —OH, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 halo alkoxy, C3-6 cycloalkyl and C6-8 aryl;
Ra and Rb are independently selected from H and C1-6 alkyl; and
y is selected from 0, 1, 2, 3, 4, 5 and 6.

### Claim 12 (depends on 11)

The compound of claim 11, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein X is O.

### Claim 13 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein the compound is of Formula (IV):

### Claim 14 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein R2 is selected from H, C1-6 alkyl, C3-6 cycloalkyl, C3-6 heterocyclyl, C6 aryl and C5-6 heteroaryl; wherein C1-6 alkyl, C3-6 cycloalkyl, C3-6 heterocyclyl, C6 aryl and C5-6 heteroaryl are each optionally substituted with 1 or more substituents selected from halogen, —CN, —OH, —N—(CH3)2, C1-6 alkyl and C1-6 haloalkyl.

### Claim 15 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein R6 is selected from H, halogen, —NH2, oxo, —OH, C1-6 alkyl, C1-6 alkoxy, C3-6 cycloalkyl and C6 aryl.

### Claim 16 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein the compound is of Formula (V):
wherein,
R1 is selected from C1-6 alkyl and C1-6 haloalkyl;
R2 is selected from H, C1-6 alkyl, C3-6 cycloalkyl, C3-6 heterocyclyl, C6 aryl and C5-6 heteroaryl; wherein C1-6 alkyl, C3-6 cycloalkyl, C3-6 heterocyclyl, C6 aryl and C5-6 heteroaryl are each optionally substituted with one or more substituents selected from halogen, —CN, —OH, —N—(CH3)2, C1-6 alkyl and C1-6 haloalkyl.

### Claim 17 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein R1 is C1-4 alkyl, wherein R1 is substituted optionally with halogen.

### Claim 18 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein R1 is selected from —CH(CH3)2, —C(CH3)3, —CF3 and —CHF2.

### Claim 19 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein R2 is selected from H, C1-6 alkyl, C3-6 cycloalkyl, C3-6 heterocyclyl, C6 aryl and C5-6 heteroaryl, wherein R2 is substituted optionally with halogen.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein R2 is selected from —CH3, —CH2CH3, —CH(CH3)2, —CH2CF3, cyclopropyl, cyclobutyl, phenyl and pyridyl; wherein —CH3, —CH2CH3, —CH(CH3)2, —CH2CF3, cyclopropyl, cyclobutyl, phenyl and pyridyl are each optionally substituted with halogen.

### Claim 23 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein R2 is selected from —CH3, —CH(CH3)2, cyclopropyl, phenyl and phenyl substituted with halogen.

### Claim 24 (depends on 1)

The compound of claim 1, or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof, wherein the compound is selected from:
1) (2S)-1-(2-(5-isopropyl-3-methyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)pyrrolidine-2-carboxamide;
2) (2S)-1-(2-(3-cyclopropyl-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)pyrrolidine-2-carboxamide;
3) (2S)-1-(2-(5-isopropyl-2,4-dioxo-3-(2,2,2-trifluoroethyl)imidazolidine-1-yl)-5,6-dihydrobenzo[f] imidazo [1,2-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
4) (2S)-1-(2-(3-(4-fluorophenyl)-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo [1,2-d] [1,4] oxazepin-9-yl)pyrrolidine-2-carboxamide;
5) (2S)-1-(2-(5-cyclopropyl-3-methyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)pyrrolidine-2-carboxamide;
6) (2S)-1-(2-(3-cyclobutyl-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)pyrrolidine-2-carboxamide;
7) (2S)-1-(2-(3-ethyl-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)pyrrolidine-2-carboxamide;
8) (2S)-1-(2-(5-difluoromethyl-3-methyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)pyrrolidine-2-carboxamide;
9) (2S)-1-(2-(5-isopropyl-2,4-dioxo-3-phenylimidazolidine-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)pyrrolidine-2-carboxamide;
10) (S)-1-(2-((S)-5-isopropyl-2,4-dioxo-3-phenylimidazolidine-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
11) (S)-1-(2-((R)-5-isopropyl-2,4-dioxo-3-phenylimidazolidine-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
12) (2S)-1-(2-(5-isopropyl-2,4-dioxo-3-(4-(trifluoromethyl)phenyl)imidazolidine-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)pyrrolidine-2-carboxamide;
13) (2S)-1-(2-(5-isopropyl-2,4-dioxo-3-propylimidazolidine-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)pyrrolidine-2-carboxamide;
14) (2S)-1-(2-(3-cyclopropyl-5-isopropyl)-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)-2-methylpyrrolidine-2-carboxamide;
15) (2S)-1-(2-(3-cyclopropyl-5-isopropyl)-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] thiazepin-9-yl)-4,4-difluoropyrrolidine-2-carboxamide;
16) (2S)-1-(2-(5-isopropyl-3-(1-methyl-1H-1,2,4-triazol-5-yl)-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
17) (2S,4S)-4-amino-1-(2-(3-cyclopropyl-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f] imidazo [1,2-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
18) (2S)-1-(2-(3-(2-fluorophenyl)-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
19) (2S)-1-(2-(3-(4-chlorophenyl)-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)pyrrolidine-2-carboxamide;
20) (2S)-4-(tertbutoxy)-1-(2-(3-cyclopropyl-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f] imidazo [1,2]-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
21) (2S)-1-(2-(3-cyclopropyl-5-isopropyl)-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)-4,4-dimethylpyrrolidine-2-carboxamide;
22) (2S)-1-(2-(3-(2,2-difluoroethyl)-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
23) (2S)-1-(2-(3,5-diisopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)pyrrolidine-2-carboxamide;
24) (2S)-1-(2-(3-cyclopropyl-5-isopropyl)-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)-4-phenylpyrrolidine-2-carboxamide;
25) (2S)-1-(2-(3-(3-chloro5-cyanophenyl)-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] thiazepin-9-yl)pyrrolidine-2-carboxamide;
26) (2S)-1-(2-(3,5-diisopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]thiazepin-9-yl)pyrrolidine-2-carboxamide;
27) (2S)-1-(2-(3-azetidin-3-yl)-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)pyrrolidine-2-carboxamide;
28) (2S)-1-(2-(3-methyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)pyrrolidine-2-carboxamide;
29) (2S)-1-(2-(5-tertbutyl-3-methyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)pyrrolidine-2-carboxamide;
30) (S)-1-(2-((R)-3-(4-fluorophenyl)-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2]-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
31) (S)-1-(2-((S)-3-(4-fluorophenyl)-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2]-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
32) (2S)-1-(2-((5R)-3-cyclopropyl-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
33) (2S)-1-(2-((5S)-3-cyclopropyl-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
34) (2S)-1-(2-(3-(2-hydroxyethyl)-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
35) (2S)-1-(2-(3-(2-fluoroethyl)-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)pyrrolidine-2-carboxamide;
36) (2S)-1-(2-(3-(2-(dimethylamino)ethyl)-5-)isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
37) (2S)-1-(2-(3-cyclopropyl-5-isopropyl)-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] thiazepin-9-yl)pyrrolidine-2-carboxamide;
38) (2S)-1-(2-(3-(6-fluoropyridin-3-yl)-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
39) (2S)-1-(2-(3-(5-fluoropyridin-3-yl)-5-isopropyl-2,4-dioxoimidazolidin1-yl)-5,6-dihydrobenzo[f]imidazo[1,2]-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
40) (2S)-1-(2-(3-(3-cyano-5-fluorophenyl)-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)-4-fluorinepyrrolidine-2-carboxamide;
41) (2S)-1-(2-(3-(3-chloropyrimidin-2-yl)-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
42) (2S)-1-(2-(3-cyclopentyl-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)pyrrolidine-2-carboxamide;
43) (2S)-1-(2-(3-(cyanomethyl)-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
44) (2S)-1-(2-(5-isopropyl-3-methyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] thiazepin-9-yl)pyrrolidine-2-carboxamide;
45) (2S)-1-(2-(3-(2,2-difluoroethyl)-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]thiazepin-9-yl)pyrrolidine-2-carboxamide;
46) (2S)-1-(2-(3-cyclopropyl-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-3-vinyl-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
47) (2S)-1-(3-chloro-2-(3-cyclopropyl-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide;
48) (2S)-1-(2-(3-cyclopropyl-5-(difluoromethyl)-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]thiazepin-9-yl)pyrrolidine-2-carboxamide;
49) (2S,3S)-1-(2-(3-cyclopropyl-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4] oxazepin-9-yl)-3-hydroxypyrrolidine-2-carboxamide;
50) (2S)-1-(2-(3-cyclopropyl-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-3-methyl-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-yl)-4-oxopyrrolidine-2-carboxamide;
51) (2S)-4-cyclohexyl-1-(2-(3-cyclopropyl-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f]imidazo [1,2-d] [1,4]oxazepin-9-yl)pyrrolidine-2-carboxamide; and
52) (2S)-1-(2-(3-cyclopropyl-5-isopropyl-2,4-dioxoimidazolidin-1-yl)-5,6-dihydrobenzo[f] imidazo [1,2-d] [1,4] thiazepin-9-yl)-5-oxopyrrolidine-2-carboxamide.

### Claim 25 (depends on 1)

A pharmaceutical composition, which comprises a) a therapeutically effective amount of at least one compound of claim 1 or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof and b) at least one pharmaceutical acceptable excipient, wherein the weight ratio of a) and b) is in the range from 0.0001 to 10.

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35 (depends on 1)

A method for the treatment or prevention of a disease mediated by PI3K, wherein the method comprising administering to said subject in need thereof a therapeutically amount of the compound of claim 1 or a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof and at least one pharmaceutical acceptable excipient, wherein the disease is cancer.

### Claim 36 (depends on 35)

The method of claim 35, wherein the PI3K include PI3Kα, PI3Kβ, PI3Kδ and/or PI3Kγ.

### Claim 37 (depends on 35)

The method of claim 35, wherein PI3K is PI3Kα.

### Claim 38

(canceled)

### Claim 39 (depends on 38)

The method of claim 38, wherein the cancer is sarcoma, prostate cancer, breast cancer, pancreatic cancer, gastrointestinal cancer, colorectal cancer, thyroid cancer, liver cancer, adrenal cancer, glioma, endometrial cancer, melanoma, kidney cancer, bladder cancer, uterine cancer, vagina cancer, ovarian cancer, multiple myeloma, esophageal cancer, leukemia, brain cancer, oral and pharyngeal cancer, laryngeal cancer, lymphoma, basal cell carcinoma, polycythemia vera, or essential thrombocythemia.

### Claim 40 (depends on 1)

A method for the treatment of cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the compound of claim 1 or a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 or a stereoisomer, geometric isomer or tautomer, or a pharmaceutically acceptable salt, solvate, chelate, non-covalent complex or prodrug thereof and at least one pharmaceutical acceptable excipient, wherein the cancer is sarcoma, prostate cancer, breast cancer, pancreatic cancer, gastrointestinal cancer, colorectal cancer, thyroid cancer, liver cancer, adrenal cancer, glioma, endometrial cancer, melanoma, kidney cancer, bladder cancer, uterine cancer, vagina cancer, ovarian cancer, multiple myeloma, esophageal cancer, leukemia, brain cancer, oral and pharyngeal cancer, laryngeal cancer, lymphoma, basal cell carcinoma, polycythemia vera, or essential thrombocythemia.

### Claim 41 (depends on 40)

The method of claim 40, wherein the subject is human.
